{
    "name": "mosunetuzumab",
    "comment": "Rx",
    "other_names": [
        "Lunsumio",
        "mosunetuzumab-axgb"
    ],
    "classes": [
        "B-Cell Lymphoma Inhibitors",
        "Antineoplastics",
        "Anti-CD20 Monoclonal Antibodies"
    ],
    "source": "https://reference.medscape.com/drug/lunsumio-mosunetuzumab-4000308",
    "pregnancy": {
        "common": [
            "Based on mechanism of action, mosunetuzumab may cause fetal harm when administered to pregnant females",
            "No data are available on use in pregnant females to evaluate drug-associated risk",
            "No animal reproductive or development toxicity studies were conducted",
            "Mosunetuzumab causes T-cell activation and cytokine release; immune activation may compromise pregnancy maintenance",
            "Human immunoglobulin G (IgG) is known to cross the placenta; therefore, mosunetuzumab may potentially transmit from mother to developing fetus",
            "Advise females of potential risk to fetus",
            "Verify pregnancy status of females of reproductive potential before initiating"
        ],
        "specific": [
            {
                "type": "Contraception",
                "description": [
                    "Females of reproductive potential: Use effective contraception during treatment and for 3 months after final dose"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "There are no data on presence of mosunetuzumab in human milk, effects on breastfed children, or effects on milk production",
            "Maternal IgG is known to be present in human milk",
            "Advise patients not to breastfeed during treatment and for 3 months after final dose"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": [
                {
                    "type": "Cytokines release syndrome ",
                    "description": [
                        "Cytokine release syndrome (CRS), including serious or life-threatening reactions, may occur",
                        "Initiate treatment with step-up dosing schedule to reduce risk of CRS",
                        "At first sign of CRS, immediately evaluate for hospitalization, manage per current practice guidelines and administer supportive care; withhold or permanently discontinue based on severity",
                        "Evaluate patients who experience CRS (or other adverse reactions that impair consciousness)",
                        "Advise patients to avoid driving and operating heavy or potentially dangerous machinery until resolution"
                    ]
                }
            ]
        },
        "contraindicators": {
            "common": [
                "None"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Based on its mechanism of action, fetal harm may occur when administered to pregnant females",
                "Can promote serious or fatal infections; monitor for signs and symptoms of infection, including opportunistic infections, and treat as needed",
                "Serious or severe cytopenias, including neutropenia, anemia, and thrombocytopenia reported; monitor complete blood cell counts during treatment"
            ],
            "specific": [
                {
                    "type": "Tumor flare",
                    "description": [
                        "Serious or severe tumor flare reported; may manifest as new or worsening pleural effusions, localized pain and swelling at sites of lymphoma lesions, and tumor inflammation",
                        "Closely monitor patients with bulky tumors or disease located near airways or a vital organ during initial therapy",
                        "Monitor for signs and symptoms of compression or obstruction due to mass effect secondary to tumor flare",
                        "If compression or obstruction develops, institute standard treatment of these complications"
                    ]
                },
                {
                    "type": "CRS",
                    "description": [
                        "CRS reported",
                        "Median onset time of CRS from start of Cycle 1 Day 1 was 5 hr, Cycle 1 Day 8 was 28 hr, Cycle 1 Day 15 was 25 hr, and Cycle 2 Day 1 was 46 hr ",
                        "Median duration of CRS was 3 days ",
                        "Clinical signs and symptoms of CRS included fever, chills, hypotension, tachycardia, hypoxia, and headache",
                        "Premedicate to reduce risk of CRS, ensure adequate hydration, and monitor following administration accordingly"
                    ]
                },
                {
                    "type": "Neurotoxicity",
                    "description": [
                        "May cause serious neurologic toxicity, including ICANS",
                        "Common neurologic toxicities were headache, peripheral neuropathy, dizziness, and mental status changes (including confusional state, disturbance in attention, cognitive disorder, delirium, encephalopathy, and somnolence).",
                        "Coadministration with drugs that can cause dizziness or mental status changes may increase the risk of neurologic toxicity.",
                        "Monitor for signs and symptoms of neurologic toxicity during treatment",
                        "Evaluate patients who experience neurologic toxicity (eg, tremors, dizziness, insomnia, severe neurotoxicity, other adverse reactions that impair consciousness)",
                        "Advise patients to avoid driving and operating heavy or potentially dangerous machinery until resolution"
                    ]
                }
            ]
        }
    },
    "interactions": [],
    "adverse effects": [
        {
            "name": "Lymphocyte count decreased",
            "percent": "100"
        },
        {
            "name": "Phosphate decreased",
            "percent": "78"
        },
        {
            "name": "Hemoglobin decreased",
            "percent": "68"
        },
        {
            "name": "WBC decreased",
            "percent": "60"
        },
        {
            "name": "Neutrophils decreased",
            "percent": "58"
        },
        {
            "name": "Platelets decreased",
            "percent": "46"
        },
        {
            "name": "CRS",
            "percent": "44"
        },
        {
            "name": "Fatigue",
            "percent": "42"
        },
        {
            "name": "Glucose increased",
            "percent": "42"
        },
        {
            "name": "Rash",
            "percent": "39"
        },
        {
            "name": "AST increased",
            "percent": "39"
        },
        {
            "name": "Gamma",
            "percent": "34"
        },
        {
            "name": "glutamyl transferase",
            "percent": "34"
        },
        {
            "name": "GGT",
            "percent": "33"
        },
        {
            "name": "increased",
            "percent": "32"
        },
        {
            "name": "Magnesium decreased",
            "percent": "32"
        },
        {
            "name": "Potassium decreased",
            "percent": "29"
        },
        {
            "name": "Headache",
            "percent": "28"
        },
        {
            "name": "ALT increased",
            "percent": "22"
        },
        {
            "name": "Pyrexia",
            "percent": "22"
        },
        {
            "name": "Musculoskeletal pain",
            "percent": "21"
        },
        {
            "name": "Cough",
            "percent": "20"
        },
        {
            "name": "Uric acid increased",
            "percent": "17"
        },
        {
            "name": "Pruritus",
            "percent": "17"
        },
        {
            "name": "Peripheral neuropathy",
            "percent": "17"
        },
        {
            "name": "Edema",
            "percent": "16"
        },
        {
            "name": "Diarrhea",
            "percent": "14"
        },
        {
            "name": "Nausea",
            "percent": "13"
        },
        {
            "name": "Dry skin",
            "percent": "12"
        },
        {
            "name": "Upper respiratory tract infection",
            "percent": "12"
        },
        {
            "name": "Chills",
            "percent": "12"
        },
        {
            "name": "Dizziness",
            "percent": "11"
        },
        {
            "name": "Abdominal",
            "percent": "11"
        },
        {
            "name": "Insomnia",
            "percent": "98"
        },
        {
            "name": "Arthralgia",
            "percent": "46"
        },
        {
            "name": "Dyspnea",
            "percent": "42"
        },
        {
            "name": "Lymphocyte count decreased",
            "percent": "40"
        },
        {
            "name": "Phosphate decreased",
            "percent": "22"
        },
        {
            "name": "Glucose increased",
            "percent": "13"
        },
        {
            "name": "Neutrophils decreased",
            "percent": "12"
        },
        {
            "name": "Uric acid increased",
            "percent": "10"
        },
        {
            "name": "WBC decreased",
            "percent": "10"
        },
        {
            "name": "Hemoglobin decreased",
            "percent": "10"
        },
        {
            "name": "Urinary tract infection",
            "percent": "9"
        },
        {
            "name": "Skin exfoliation",
            "percent": "7"
        },
        {
            "name": "Platelets decreased",
            "percent": "6"
        },
        {
            "name": "GGT increased",
            "percent": "4.4"
        },
        {
            "name": "ALT increased",
            "percent": "4.4"
        },
        {
            "name": "Potassium decreased",
            "percent": "2.2"
        },
        {
            "name": "Rash",
            "percent": "2.2"
        },
        {
            "name": "AST increased",
            "percent": "1.1"
        },
        {
            "name": "CRS",
            "percent": "1.1"
        },
        {
            "name": "Upper respiratory infection",
            "percent": "1.1"
        },
        {
            "name": "Pyrexia",
            "percent": "1.1"
        },
        {
            "name": "Edema",
            "percent": "1.1"
        },
        {
            "name": "Chills",
            "percent": "1.1"
        },
        {
            "name": "Peripheral neuropathy",
            "percent": "1.1"
        },
        {
            "name": "Musculoskeletal pain",
            "percent": "1.1"
        },
        {
            "name": "Dyspnea",
            "percent": null
        },
        {
            "name": "Abdominal pain",
            "percent": null
        },
        {
            "name": "Urinary tract infection",
            "percent": null
        }
    ]
}